Table 5.
The interactions between lipid biomarkers on coronary severity using logistic regression analysis.
| GS (0) | Total | Men | |||||
|---|---|---|---|---|---|---|---|
| GS (1–23) | GS (≥24) | P for trend | GS (1–23) | GS (≥24) | P for trend | ||
| TC + apoB | Reference | 1.05[1.00–1.10] | 1.08[1.02–1.13] | 0.005 | 1.04[0.97–1.12] | 1.11[1.04–1.19] | <0.001 |
| TC + Lp(a)* | Reference | 1.02[0.98–1.06] | 1.06[1.02–1.10] | 0.002 | 1.01[0.96–1.07] | 1.07[1.02–1.12] | 0.003 |
| TC + PCSK9* | Reference | 1.01[0.97–1.06] | 1.06[1.01–1.11] | 0.018 | 1.00[0.94–1.07] | 1.08[1.02–1.15] | 0.006 |
| TC + apoC3* | Reference | 1.01[0.95–1.03] | 1.02[0.97–1.08] | 0.338 | 0.95[0.88–1.03] | 1.03[0.97–1.11] | 0.157 |
| HDL-C + apoA1 | Reference | 1.00[0.86–1.17] | 0.76[0.63–0.91] | 0.008 | 0.97[0.77–1.24] | 0.68[0.53–0.89] | 0.004 |
| LDL-C + apoB | Reference | 1.05[0.99–1.12] | 1.11[1.04–1.18] | 0.002 | 1.07[0.97–1.17] | 1.17[1.07–1.27] | <0.001 |
| LDL-C + Lp(a)* | Reference | 1.02[0.98–1.07] | 1.09[1.04–1.14] | <0.001 | 1.02[0.96–1.09] | 1.10[1.04–1.17] | <0.001 |
| LDL-C + PCSK9* | Reference | 1.02[0.97–1.08] | 1.10[1.04–1.16] | <0.001 | 1.03[0.96–1.11] | 1.13[1.05–1.22] | <0.001 |
| LDL-C + apoC3* | Reference | 1.01[0.94–1.05] | 1.06[1.01–1.14] | 0.041 | 1.01[0.93–1.08] | 1.10[1.00–1.21] | 0.011 |
| Non-HDL-C + apoB | Reference | 1.05[0.99–1.11] | 1.09[1.03–1.16] | 0.003 | 1.04[0.96–1.13] | 1.13[1.05–1.22] | <0.001 |
| Non-HDL-C + Lp(a)* | Reference | 1.02[0.98–1.07] | 1.08[1.04–1.13] | <0.001 | 1.01[0.95–1.07] | 1.10[1.04–1.16] | <0.001 |
| Non-HDL-C + PCSK9* | Reference | 1.01[0.96–1.06] | 1.08[1.03–1.14] | 0.003 | 1.00[0.93–1.07] | 1.11[1.04–1.19] | <0.001 |
| Non-HDL-C + apoC3* | Reference | 1.01[0.92–1.03] | 1.04[1.00–1.10] | 0.047 | 0.95[0.87–1.03] | 1.06[1.00–1.15] | 0.042 |
| ApoA1 + largeHDL-C* | Reference | 0.97[0.73–1.30] | 0.69[0.51–0.94] | 0.019 | 0.78[0.52–1.17] | 0.50[0.33–0.77] | 0.002 |
| ApoB + Lp(a)* | Reference | 1.23[1.05–1.43] | 1.37[1.17–1.61] | <0.001 | 1.26[1.02–1.55] | 1.47[1.19–1.80] | <0.001 |
| ApoB + PCSK9* | Reference | 1.28[1.06–1.54] | 1.46[1.21–1.77] | <0.001 | 1.40[1.06–1.79] | 1.71[1.33–2.21] | <0.001 |
| ApoB + apoC3* | Reference | 1.10[0.98–1.36] | 1.25[1.03–1.58] | 0.027 | 1.12[0.87–1.54] | 1.44[1.06–1.95] | 0.009 |
| ApoB + sdLDL-C* | Reference | 1.17[0.89–1.54] | 1.22[0.93–1.60] | 0.148 | 1.22[0.83–1.78] | 1.31[0.91–1.89] | 0.134 |
| PCSK9* + sdLDL-C* | Reference | 1.09[0.92–1.30] | 1.16[0.98–1.37] | 0.095 | 1.13[0.90–1.42] | 1.21[0.97–1.51] | 0.087 |
| ApoC3* + sdLDL-C* | Reference | 1.05[0.87–1.27] | 1.10[0.91–1.33] | 0.297 | 1.09[0.85–1.40] | 1.17[0.92–1.48] | 0.193 |
Multiple logistic regression analyses were performed and ORs [95% CIs] were showed with adjustment for age, gender, hypertension, HbA1c, current smoking and hs-CRP. The interaction terms as Table 4.
The bold values indicated statistical significance and were bolded to improve the readability of the table. *Log-transformed data.
Abbreviations as Table 1.